Feasibility · Type 2 diabetes · Phase II–III
Type 2 diabetes trial feasibility, cited to its source.
Type 2 diabetes has a large prevalent population, so the feasibility risk shifts from "are there enough patients" to "can we enroll fast enough against heavy competition and tight eligibility windows." Background-therapy and HbA1c criteria do most of the cohort filtering.
Deterministic, re-runnable feasibility scoring.
What drives feasibility here
The questions that decide go or no-go.
The traps that are specific to type 2 diabetes — the ones a generic prevalence estimate will miss.
Benchmarks
The numbers come from the run.
We do not hand-write counts onto a marketing page. For type 2 diabetes, the registry and literature figures are pulled when you run the indication, each one carrying its source record and a snapshot date.
Each figure arrives with the source record it came from and the date it was read, so your team — and the sponsor reviewing the bid — can open the same query and see the same answer.
Grounded in public data
Where the type 2 diabetes read comes from.
Every figure links back to its source record with a snapshot date, so your team and the sponsor can re-verify it. Probability-of-success reads are directional — priors drawn from public precedent, not calibrated predictions — and are labelled that way in the verdict.
Also searched as: T2DM trials, diabetes feasibility.
See a cited verdict for type 2 diabetes.
Send us a protocol — or just a molecule and an indication. We'll return a fully cited feasibility assessment you can trace, line by line, back to public data — yours to defend in a bid, take to your board or investment committee, or hand to a regulator.